Anti-Human CD44 – Purified (Clone F10-44-2)

Anti-Human CD44 – Purified (Clone F10-44-2)

Product No.: C562

[product_table name="All Top" skus="C562"]

- -
- -
Clone
F10-44-2
Target
CD44
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Pgp-1, H-CAM
Isotype
IgG2a
Applications
FC
,
IHC FFPE
,
IP

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
Purified Human T Cells
Product Concentration
0.1 mg/ml
Formulation
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Storage and Handling
For use within 1 month of purchase store at 2-8°C. For long term storage freeze working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone F10-44-2 recognizes human CD44.
Antigen Distribution
CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.
Background
CD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency.

Antigen Details

Ligand/Receptor
Hyaluronan, MIP-1β, fibronectin, collagen
PubMed
NCBI Gene Bank ID

References & Citations

1. Leukocyte Typing V (1995) Oxford University Press 2. Shi, S. R. et al. (1995) Cell Vision 2:6 3. Stauder, R. et al. (1995) Immunologist 3:78 4. Favaloro, E. (1993) Immunol. Cell Biol. 71:571 5. Goldstein, L. A. et al. (1990) Immunogenetics 32(6):389 6. Leukocyte Typing IV (1989) Oxford University Press 7. Leukocyte Typing III (1987) Oxford University Press
Flow Cytometry
IHC FFPE
Immunoprecipitation Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.